Cellect Biotechnology Ltd. (APOP)’s Financial Results Comparing With EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG)

This is a contrast between Cellect Biotechnology Ltd. (NASDAQ:APOP) and EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellect Biotechnology Ltd. 1 0.00 N/A -0.85 0.00
EyeGate Pharmaceuticals Inc. 4 3.59 N/A -0.19 0.00

Table 1 highlights Cellect Biotechnology Ltd. and EyeGate Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Cellect Biotechnology Ltd. 0.00% 0% 0%
EyeGate Pharmaceuticals Inc. 0.00% -69.3% -48.4%

Insider and Institutional Ownership

Cellect Biotechnology Ltd. and EyeGate Pharmaceuticals Inc. has shares held by institutional investors as follows: 0% and 40.1%. Insiders held roughly 54.73% of Cellect Biotechnology Ltd.’s shares. Insiders Comparatively, held 4.5% of EyeGate Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellect Biotechnology Ltd. 17.99% 22.45% -31.82% -73.33% -90.14% -71.43%
EyeGate Pharmaceuticals Inc. -7.15% -14.35% -23.52% -57.85% -61.04% -55.6%

For the past year Cellect Biotechnology Ltd.’s stock price has bigger decline than EyeGate Pharmaceuticals Inc.

Summary

On 5 of the 7 factors EyeGate Pharmaceuticals Inc. beats Cellect Biotechnology Ltd.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.